DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Change in Directorate
As per enclosed letter.25-05-2024
25-05-2024
DIVI'S LABORATORIES LTD. - 532488 - Audited Financial Results For The Quarter And Year Ended March 31, 2024
As per enclosed letter.25-05-2024
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 25, 2024
As per enclosed letter.25-05-2024
DIVI'S LABORATORIES LTD. - 532488 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year end 31.03.202421-05-2024
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of earnings conference call for 4th quarter and year ended FY 2023-24 to be held on May 25, 2024 at 14:30 hrs (IST).20-05-2024
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended March 31, 2024 And Consideration Of Dividend, If Any, On The Equity Shares Of The Company For The Financial Year 2023-24.
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 ,inter alia, to consider and approve Audited financial results for the quarter and year ended March 31, 2024 and recommend dividend, fi any, on the equity shares of the Company for the financial year 2023-24.15-05-2024
DIVI'S LABORATORIES LTD. - 532488 - Information About Proposed Capacity Addition
Information about proposed capacity addition as per enclosed disclosure.25-04-2024
DIVI'S LABORATORIES LTD. - 532488 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyDIVI''S LABORATORIES LTD. 2CIN NO.L24110TG1990PLC011854 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: M Satish Choudhury Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: L Kishore Babu Designation: Chief Financial Officer EmailId: [email protected] Date: 12/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.12-04-2024
DIVI'S LABORATORIES LTD. - 532488 - Compliance Certificate For The Year Ended March 31, 2024
Submission of compliance certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015.08-04-2024